In human epidermal growth-factor receptor 2-positive (HER2+) breast cancer, panobinostat combined with trastuzumab (anti-HER2) stimulates the release of CXCR3-reactive chemokines and enhances the recruitment of tumor-associated natural killer (NK) cells to achieve eradication of tumors (Medon et al., 2017). The gene discussed is ERBB2; the disease is breast carcinoma.